17個 藥品獨家品種 醫保 瞄準 降價

多省份下調抗癌藥價格 目錄外醫保準入談判不斷推進 鉅亨網新聞中心※來源：財華社2018/07/24據新京報消息，近日，多個省份藥採平台陸續傳來藥品降價的消息。6月29日，湖北省公立醫院藥品(耗材)供應保障平台發佈公告稱，響應國家稅改政策，根據企業申請，下調輝瑞15個品種、20個品規藥品掛網價格，降幅3.4%-10.2%。7月4日，北京醫藥集中採購服務中心發佈提醒，輝瑞和西安楊森等公司已通過北京市藥品陽光採購自主降價功能，其中不乏抗癌藥物。以克唑替尼(賽可瑞)為例，該藥主要用於治療非小細胞肺癌，於2011年8月獲得美國食藥監局優先審批批準上市。原掛網價5.34萬元的克唑替尼(250mg規格)，每盒將降價2078元，降價幅度為3.9%。值得註意的是，醫保目錄外的獨家抗癌藥，其醫保準入談判也在不斷推進中。7月12日，國家醫保局表示，將以省為單位，開展抗癌藥專項集中採購。截至目前，湖北、甘肅、北京、四川、山東等多個省份已開始對抗癌藥價格進行調整，四川是首個公佈關於抗癌藥專項談判的省份，該談判已於7月13日啓動。財政部此前公佈的103個抗癌製劑清單中，已有82種被納入醫保目錄(2017年版)和36個談判品種，這些品種也將成為抗癌藥專項集中採購的重點。在剩餘的21個非醫保品種中，有17個為獨家品種(13個為外企獨家，4個為國產獨家)，這些或將是本次準入談判的重點。來源：新京報更多精彩內容 請登陸財華智庫網 (http://www.finet.com.cn) 財華香港網 (http://www.finet.hk)或 現代電視 (http://www.fintv.com)

Human breast milk KILLS over 40 types of cancer

 Monday, July 23, 2018 (Natural News) Conventional cancer treatments like chemo and radiation therapy are known for causing an array of undesirable health effects. Even so, the cancer industry continues to parade their flagship products as the end-all be-all of cancer treatment. But many people believe that medicine shouldn't hurt. Perhaps that's why scientists continue to look for other, less damaging options. Research continues to point to an array of herbs and plants as a means of natural cancer treatment, but the latest science has identified a surprising source of cancer-killing compounds: Human breast milk.Mother's milk is known for containing a bevy of antibodies and other beneficial compounds for newborn babies, to protect them from all the harmful things in the world while their immune system matures. So in a way, as strange as it sounds, the notion that breast milk may hold the key to fighting cancer naturally, really isn't that surprising at all.

Breast milk as a cancer-killer Professor Catharina Svanborg has been paving the road to capitalizing on breast milk's cancer-fighting abilities out of her lab at Lund University in Sweden. Specifically, the professor has been working on a way to bind a breast milk protein known as alpha-lactalbumin to oleic acid, a fatty acid found in olive oil, nuts and seeds.The cancer-killing combination she's dubbed HAMLET (an acronym for human alpha-lactalbumin made lethal to tumor cells) has shown great success in laboratory applications, shrinking brain, bladder and colon tumors with ease. Tests involving animal and human cancer cell lines have shown that HAMLET is effective against at least 40 types of cancer.The power of the elements: Discover Colloidal Silver Mouthwash with quality, natural ingredients like Sangre de Drago sap, black walnut hulls, menthol crystals and more. Zero artificial sweeteners, colors or alcohol. Learn more at the Health Ranger Store and help support this news site."Looking down the microscope at the dying tumor cells, we were quite excited, especially when the experiment was repeated and showed the same effect twice. We had used non-cancerous cells for a long time in similar experiments and they had not died," Svanborg told The Telegraph, speaking about the amazing way breast milk kills cancer.But the funny thing is that Svanborg discovered all of this two decades ago.

Overcoming skepticism and doubt Svanborg reportedly went onto patent her confirmed discovery in 1995. She published her research, hoping to take the cancer industry by storm with her amazing find. But instead of being met with praise and applause, she was simply met with disbelief."There was a certain degree of skepticism. It is about being let into the cancer community more than anything else," the professor contended. As a university professor and immunologist, Svanborg wasn't considered part of the cancer or pharmaceutical industries — and she struggled to have her work taken seriously. As a specialist in infectious diseases, and a threat to the profit-driven cancer industry, her research on breast milk and cancer fell on deaf ears.But Svanborg was determined and would not be deterred. "One has to be stubborn when it is a journey into unchartered territory," she said. For the last 20 years, Svanborg has continued her research and continues to turn her skeptics into believers, one by one."It is an absolutely thrilling project. If you hang in there, it opens up new ways of thinking about protein structure, cell biology and the nature of cancer. People are coming around to the fact that this is very well supported by in-depth studies," Svanborg contended. The team recently developed a way to mass produce HAMLET, which means it could soon become a widely used cancer treatment. Her game-changing discovery promises to kill cancer cells without damaging health cells — a feat that eludes conventional treatments like chemo.Though HAMLET still has a ways to go before becoming an approved form of treatment that's available to the masses, Svanborg remains hopeful. You can learn more about alternative cancer treatments at AntiCancer.news.

漢達 攻P4 : 夥伴Par Pharma 拿下Quetiapine XR Tablet & Dexlansoprazole DR Capsules 首發學名藥

漢達拚轉型 掌握研發專利 2018年07月23日 04:11 工商時報 文／陶駿維 漢達生技（6620）於7月17日召開法人說明會，宣布推出獨特創新的藥物製劑技術平台「ONCORE」，應用於具有專利保護的505（b）（2）新藥開發，2018年預計投入約美金600萬元在505（b）（2）新藥開發上，預期未來可為漢達帶來長期穩定的獲利。漢達董事長劉芳宇博士表示，有鑑於學名藥市場競爭激烈，漢達於2017年起積極轉型，以具有專利保護的505（b）（2）新藥為重點研發項目。漢達獨特的藥物傳輸技術，針對酪胺酸激脢抑制劑（Tyrosine kinase inhibitor）之物理化學性質及藥物動力學特性加以改善，增進抗癌藥物臨床使用的安全及有效性，降低、減少甚至消除抗癌藥物及相關藥品的侷限性，使病患更安全便利的服用藥物，進而提升病患的生活品質。目前從事藥物劑型研究及製劑處方設計開發，成功將多項藥物控釋系統平台技術應用於產品開發中，已獲得及申請之專利共計約20項。漢達過去在高技術門檻學名藥（PIV）研發上繳出亮眼的成績單，2016年11月，與合作夥伴Par Pharmaceutical, Inc.共同開發治療思覺失調症的高技術門檻之首發學名藥（Quetiapine XR Tablet），於美國上市銷售後，為漢達挹注豐厚營收；另一項治療胃食道逆流用藥（Dexlansoprazole DR Capsules），於2017年4月，由合作夥伴Par Pharmaceutical, Inc.取得美國FDA學名藥審查最終核准，為美國市場重磅級首發學名藥，Dexlansoprazole DR Capsules在中國市場，將由策略夥伴「復星醫藥」旗下公司，負責CFDA註冊及銷售事宜。漢達和合作夥伴已共同開發完成6項學名藥產品，並分別向加拿大藥政單位或美國FDA及中國CFDA提出申請，其中有2項產品已順利取得美國FDA學名藥審查最終核准（Final Approval），為首家接受審查之首發（FTF）學名藥產品。漢達係以藥物劑型及處方設計為基礎之研發型專業製藥公司，以台灣作為全球營運及製劑研發中心，藉由子公司Handa Pharmaceuticals, LLC，以及孫公司杭州漢達醫藥科技有限公司，跨入世界前兩大藥物銷售區域（美國、中國）。漢達105年度合計營收2.11億元，每股獲利0.29元；106年度合計營收5.38億元，每股獲利2.81元，獲利為目前生技公司在興櫃市場的資優生。劉芳宇指出，「研發」是漢達的核心價值，漢達的研發團隊具有國際性藥物研發能力及經驗，專注於開發具有高度市場價值的505（b）（2）新藥及高技術門檻之利基型學名藥，透過共同開發或授權的低風險經營模式，達到永續穩健經營的目標。(工商時報)

(台大 邱瀚模 醫師) 定期篩檢 本不會發生大腸癌

大腸癌連9年蟬聯十大癌症榜首 醫師：其實可預防 發稿時間：2018/07/20 （中央社記者張茗喧台北20日電）「心海羅盤」主持人葉耀星罹大腸癌，卻堅信可靠意志力抗癌不治療，日前辭世。醫師表示，台灣人對於癌症普遍存在迷信，寧信偏方也不好好治療，更有約40%台灣人從沒做過腸癌篩檢。根據衛生福利部統計，大腸癌已連續9年蟬聯癌症發生人數首位，平均每13人就有1人終其一生會罹患大腸癌。然而，大腸癌並沒有外界想像中那麼恐怖，而且是最容易預防的癌症。台大醫院內科部主治醫師邱瀚模今天受訪時表示，大腸癌是生長相當緩慢的癌症，在初期會先出現癌前病變，只要能定期篩檢、及早發現並切除，根本不會發生大腸癌，即便是0期、1期的大腸癌，也很有機會根治。不過，台灣人觀念中經常認為，沒有症狀就不需要篩檢，即便罹癌也寧可拜神、嘗試偏方，也不願好好接受正規治療。邱瀚模指出，在歐洲國家，定期接受大腸癌篩檢的篩檢率約70%，但台灣有約60%民眾至少做過一次篩檢，每2年定期篩檢率僅有40%，值得注意的是，即便政府提供免費大腸癌篩檢，仍有40%的民眾從未做過腸癌篩檢。這種不好好接受篩檢的人，一旦罹癌就得耗費大量醫療資源治療，因此近年國外正在討論，若不按時接受篩檢，未來罹病時應提高醫療費用自負額。邱瀚模也提醒，一名年過50歲的民眾若是從未做篩檢，有約7%機率會罹患大腸癌，等於15人當中就有1人會罹患大腸癌，不可輕忽。他呼籲，想遠離大腸癌，應少吃香腸、臘肉、培根等加工肉品及豬、羊、牛等紅肉，改吃魚肉、瘦雞肉等白肉，平時也應養成運動習慣，年過50歲定期接受篩檢。（編輯：方沛清）

核酸医薬の開発推進へ、AMED研究班きょう始動品質・安全性評価、20年度末めどにガイダンス案

2018/7/24 04:30核酸医薬の開発推進や効率化に向けて、国立医薬品食品衛生研究所と大阪大の研究者を中心とする研究班が、品質・安全性評価に関する研究をスタートさせる。日本医療研究開発機構（AMED）の医薬品等規制調和・